|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | High-intensity focused ultrasound ablation:An effective bridging therapy for hepatocellular carcinoma patients显示文摘AIM:To analyze whether high-intensity focused ultrasound(HIFU) ablation is an effective bridging therapy for patients with hepatocellular carcinoma(HCC).METHODS:From January 2007 to December 2010,49 consecutive HCC patients were listed for liver transplantation(UCSF criteria).The median waiting time for transplantation was 9.5 mo.Twenty-nine patients received transarterial chemoembolization(TACE) as a bringing therapy and 16 patients received no treatment before transplantation.Five patients received HIFU ablation as a bridging therapy.Another five patients with the same tumor staging(within the UCSF criteria) who received HIFU ablation but not on the transplant list were included for comparison.Patients were comparable in terms of Child-Pugh and model for end-stage liver disease scores,tumor size and number,and cause of cirrhosis.RESULTS:The HIFU group and TACE group showed no difference in terms of tumor size and tumor number.One patient in the HIFU group and no patient in the TACE group had gross ascites.The median hospital stay was 1 d(range,1-21 d) in the TACE group and two days(range,1-9 d) in the HIFU group(P < 0.000).No HIFU-related complication occurred.In the HIFU group,nine patients(90%) had complete response and one patient(10%) had partial response to the treatment.In the TACE group,only one patient(3%) had response to the treatment while 14 patients(48%) had stable disease and 14 patients(48%) had progressive disease(P = 0.00).Seven patients in the TACE group and no patient in the HIFU group dropped out from the transplant waiting list(P = 0.559).CONCLUSION:HIFU ablation is safe and effective in the treatment of HCC for patients with advanced cirrhosis.It may reduce the drop-out rate of liver transplant candidate. | Tan To Cheung Sheung Tat Fan See Ching Chan Kenneth SH Chok Ferdinand SK Chu Caroline R Jenkins Regina CL Lo James YY Fung Albert CY Chan William W Sharr Simon HY Tsang Wing Chiu Dai Ronnie TP Poon Chung Mau Lo | 2013 | World Journal of Gastroenterology2013，19，20： | 23 |
| 2 | Hepatitis B virus genotypes in the United States: results of a nationwide study显示文摘 | Chi—Jen Chu Emmet B. Keeffe Steven—Huy Han Robert P. Perrillo Albert D. Min Consuelo Soldevila-Pico William Carey Robert S. Brown Velimir A. Luketic Norah Terrault Anna S.F. Lok | 2003 | Gastroenterology2003，，2： | 1 |
| 3 | D2-40, a novelmonoclonal antibody against theM2A antigen as a marker to distinguish hemangioblastomas from renal cell carcinomas 显示文摘 | Subhojit Roy Albert Chu John Q | 2005 | Acta Neuropathol(Berl)2005，109，5： | 1 |
| 4 | Radiological prognosticators of hepatocellular carcinoma treated by hepatectomy显示文摘BACKGROUND: Hepatectomy is the main curative treatment for hepatocellular carcinoma (HCC), but postoperative long- term survival is poor. Preoperative radiological features of HCC displayed by computed tomography or magnetic resonance imaging could serve as additional prognostic factors. This study aimed to identify preoperative radiological features of HCC that may be of prognostic significance in hepatectomy. METHODS: Ninety-two patients who underwent hepatectomy for HCC were included in this study. Preoperative radiological features including tumor number, size, location (peripheral, middle, central), portal vein invasion, hepatic vein invasion, and presence of pseudo-capsule were analyzed in relation to survival. RESULTS: With a median follow-up period of 41.7 months, the 1-, 3- and 5-year overall survival rates were 85%, 65% and 58%, respectively. Univariate analysis showed that portal vein invasion and absence of pseudo-capsule were significant prognostic factors for overall survival, while all the examined radiological features were prognostic factors for disease-free survival. Multivariate analysis for overall survival found no significant factor. On multivariate analysis for disease-free survival, patients who had tumors with portal vein invasion had poorer survival with a hazard ratio of 2.26 (95% CI, 1.05-4.91; P=0.038) and patients with single nodular HCC or pseudo-capsulated HCC had better survival with a hazard ratio of 0.50 (95% CI, 0.27-0.94; P=0.032) and 0.38 (95% CI, 0.14-0.99; P=0.048), respectively. CONCLUSIONS: Demonstrable pseudo-capsule of HCC and solitary HCC on imaging and absence of portal vein invasionare features associated with better disease-free survival after hepatectomy. These features may guide treatment planning for HCC. | Kevin KW Chu See Ching Chan Sheung Tat Fan Kenneth SH Chok Tan To Cheung William W Sharr Albert CY Chan Chung Mau Lo | 2012 | Hepatobiliary & Pancreatic Diseases International2012，11，6： | 1 |
| 5 | Hierarchical modeling identifies novel lung cancer susceptibility variants in inflammation pathways among 10,140 cases and 11,012 controls显示文摘 | Darren R. Brenner Paul Brennan Paolo Boffetta Christopher I. Amos Margaret R. Spitz Chu Chen Gary Goodman Joachim Heinrich Heike Bickeb?ller Albert Rosenberger Angela Risch Thomas Muley John R. McLaughlin Simone Benhamou Christine Bouchardy Juan Pablo Lew | 2013 | Human Genetics2013，，： | 1 |
| 6 | D2 - 40,a novelmonoclonal antibody against the M2A antigen as a marker distinguish hemangio- blastomas from renal cell careinomas显示文摘 | Subhojit Roy Albert Chu John Q | 2005 | ActaNeuropathol (Berl)2005，109，5： | 1 |
| 7 | D2-40,a novelmonoclonal body against theM2A antigen as a marker todistinguishhemangioblastomas from renal cell carcinomas显示文摘 | Subhojit Roy Albert Chu John Q | 2005 | Acta Neuropathol(Berl)2005，109，5： | 1 |
| 8 | Chicken HSP70 DNA vaccine inhibits tumor growth in a canine cancer model显示文摘 | Wen-Ying Yu Tien-Fu Chuang Cécile Guichard Hanane El-Garch Dominique Tierny Albert Taiching Laio Ching-Si Lin Kuo-Hao Chiou Cheng-Long Tsai Chen-Hsuan Liu Wen-Chiuan Li Laurent Fischer Rea-Min Chu | 2011 | Vaccine2011，，18： | 1 |
| 9 | D2-40,a novel monoclonal antibody against the M2A antigen as a marker to distinguish hemangioblastomas from renal cell carcinomas显示文摘 | Subhojit Roy Albert Chu John Q | 2005 | Acta Neuropathol (Berl)2005，109，5： | 1 |
| 10 | Colorectal Chemoprevention Pilot Study (SWOG-9041), Randomized and Placebo Controlled: The Importance of Multiple Luminal Lesions显示文摘 | David Z.J. Chu Michael A. Hussey David S. Alberts Frank L. Meyskens Cecilia M. Fenoglio-Preiser Saul E. Rivkin Glenn M. Mills Jeffrey K. Giguere Charles D. Blanke Gary E. Goodman | 2011 | Clinical Colorectal Cancer2011，，4： | 1 |
| 11 | Adenoma Recurrences After Resection of Colorectal Carcinoma: Results From the Southwest Oncology Group 9041 Calcium Chemoprevention Pilot Study显示文摘 | David Z. J. Chu Kari Chansky David S. Alberts Frank L. Meyskens Cecilia M. Fenoglio-Preiser Saul E. Rivkin Glenn M. Mills Jeffrey K. Giguere Gary E. Goodman James L. Abbruzzese Scott M. Lippman | 2003 | Annals of Surgical Oncology2003，，8： | 1 |
| 12 | Emergency ABO-incompatible living donor liver transplant for patients with ultrahigh MELD scores显示文摘To the Editor:A 49-year-old Chinese man with treatment-naive chronic hepatitis B presented with a one-week history of jaundice when admitted to our hospital.On admission,his bilirubin was 704μmol/L,alanine aminotransferase 180 U/L,international normalized ratio 2.4,creatinine 140μmol/L,and Model for End-stage Liver Disease(MELD)score 35.His serum HBV DNA was 64.7 IU/mL,and he was commenced on entecavir.Nonetheless,he developed acute-onchronic liver failure on day 28 with grade 2 hepatic encephalopathy and a MELD score of 40(bilirubin 709μmol/L,international normalized ratio 3.3,creatinine 181μmol/L). | Kevin KW Chu Kenneth SH Chok James YY Fung Albert CY Chan Wing Chiu Dai Chung Mau Lo | 2019 | Hepatobiliary & Pancreatic Diseases International2019，18，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员